BOSTON, Nov. 17, 2025 — Nanoramic, Inc. (“Nanoramic”), a pioneer in advanced batteries, today announced it has secured a total of $54 million for its Series 1 equity financing. The round includes a recent investment from new partner PEP Capital, as well as repeat investments following existing participation in this round from Samsung Ventures and Top Material.

This financing round also includes prior investments from co-leads General Motors Ventures and Catalus Capital, alongside ITOCHU Corporation, Fortistar Capital, and WindSail Capital Group. The participation from a world-class syndicate of new and existing investors underscores significant market confidence in Nanoramic’s technology and its clear path to commercial adoption across a broad range of battery applications.

Nanoramic is working with key strategic partners including Samsung SDI, General Motors, and other industry leaders to accelerate the global deployment of Nanoramic’s Neocarbonix® products under an asset-light business model. This follows a successful 2025, which saw the company complete key qualification programs with public and private sector partners across multiple applications and chemistries. Today, Nanoramic’s standardized Neocarbonix® products are qualified and available via manufacturing partners across the globe. The company is positioned to support GWh-scale demand, with commercial shipments scaling up and shifting to global manufacturing sites in 2026.

Nanoramic’s proprietary Neocarbonix® technology and products are a force multiplier for the battery industry, designed to drop into existing manufacturing lines for rapid adoption. It is a PFAS “forever chemical”-free solution that eliminates the need for conventional NMP solvents, enhancing manufacturing sustainability and worker safety. The technology delivers far-reaching improvements in battery cost, energy density, power, and fast-charging performance.

“Samsung Ventures is excited to continue our support for Nanoramic given the significant progress made over the past year. We continue to believe in their technology and its potential to impact multiple energy storage applications through lower cost, higher performance, or reduced environmental impact,” said a representative from Samsung Ventures.

Brent Saiontz, Partner at PEP Capital, said, “As global energy demand continues to surge, advanced battery innovation is essential. We’re proud to support Nanoramic as they commercialize a battery platform that delivers superior performance at lower cost. With broad applicability across industries and seamless integration into existing technologies and manufacturing lines, Nanoramic provides a practical, scalable path to better batteries today.”

“As co-leads of this financing, we are impressed by Nanoramic’s execution and success in transitioning from validation towards global commercialization. Their asset-light, drop-in solution provides a clear path to market adoption, addressing the energy storage industry’s critical needs. We are proud to support their scale-up as they become a key leader in the energy transition,” said Saif Qazi, Vice President at Catalus Capital.

John Cooley, Nanoramic CEO and Founder, said, “With the final closing of this round, Nanoramic has secured a portfolio of best-in-class customers and partners. These partnerships will help bring mass production of our Neocarbonix product to all major lithium-ion applications by 2027. Our asset-light model will benefit from the trading expertise of ITOCHU, the manufacturing expertise of Top Material, and the commercial prowess and broad application exposure of our most major customers including General Motors, Samsung SDI, and others. At Nanoramic, we will continue to successfully execute our plans toward global adoption now accelerated with the support of our new partners.”

About Nanoramic, Inc.
Nanoramic, Inc. is an industry-leading energy storage and advanced materials company that has developed an innovative battery technology, Neocarbonix®. Nanoramic is commercializing Neocarbonix to transform energy storage for all battery applications: increasing energy density and longevity, while reducing costs and improving sustainability. Nanoramic works with some of the world’s largest automakers, consumer electronics companies, and battery manufacturers to develop and commercialize batteries made with Neocarbonix. To learn more, visit www.nanoramic.com.

SOURCE Nanoramic, Inc.

First Closing of Breakthrough Properties Growth Portfolio II  Builds Upon Successes of Inaugural Fund

LOS ANGELES, Nov. 17, 2025 — Breakthrough Properties, a joint venture of Tishman Speyer and Bellco Capital, today announced the first closing for its Breakthrough Properties Growth Portfolio II fund, which will invest in a diversified portfolio of Class A life science real estate across leading innovation clusters in the United States and Europe.

Breakthrough’s $430 million first closing amount reflects both direct capital and co-investment commitments and builds upon the achievements of Breakthrough’s $3 billion inaugural life science investment fund, which closed in 2022.

The only dedicated life science real estate manager active across the U.S., U.K. and continental Europe, Breakthrough used its first fund to invest in a market-leading portfolio of projects spanning nearly six million square feet. Its current life science assets encompass purpose-built developments, value-add conversions and core/core+ properties across eight preeminent biopharma markets. 

Breakthrough’s signature projects, such as Torrey Heights in San Diego, One Helix in Amsterdam and One Milestone at the forthcoming Harvard Enterprise Research Campus in Boston, have already attracted many of the world’s leading life science firms. More than 60 percent of its global portfolio is currently leased to leading investment-grade companies, including Pfizer, AstraZeneca, Eli Lilly, Bristol Myers Squibb, BD and Roche. 

Participants in the first closing included institutional and private investors such as global asset managers, investment advisors, pension funds and family offices. Breakthrough, which plans to hold subsequent closings for the fund in 2026, will invest across a range of life science asset profiles and markets, targeting a blended value-add return.

“This closing aligns with the most compelling investment window we’ve seen in years,” said Dan Belldegrun, Chief Executive Officer for Breakthrough Properties. “Transitory market dynamics have generated the opportunity to acquire high quality assets at heavily disrupted pricing and to capitalize on the sector’s long-term structural tailwinds. The incredible power of science is only accelerating, generalist investors are retreating and new supply is entirely shut off. We believe these are precisely the ingredients for a fantastic investment vintage. We’re grateful to our partners for supporting Breakthrough’s exciting next chapter.”

Tishman Speyer CEO and Breakthrough Co-Chairman Rob Speyer said, “The first close of Breakthrough’s second fund demonstrates the trust we’ve built with our investment partners. Our initial fund delivered proof of concept. This fund allows us to flex all of Breakthrough’s muscles and scale an exceptional portfolio.”

Breakthrough Properties Chief Investment Officer Dan D’Orazi added, “Our investment approach will continue to center around Class A assets in prime locations, with an emphasis on attractive entry points and improving market fundamentals. Breakthrough’s dedicated life science platform, supported by our partners at Tishman Speyer and Bellco Capital, forms a deep expertise, relationship network and global reach that uniquely positions us to capitalize on opportunities emerging across the market.”

Driven by Bellco Capital and Tishman Speyer’s demonstrated success and established networks, 70 percent of Breakthrough’s leasing has been secured through direct relationships with premier life science users. 

Breakthrough is led by an experienced management team with a proven track record of acquiring, developing and operating life science real estate. The firm seeks to employ a user-driven approach and to provide unique insights on where science is trending to deliver a higher standard of quality with a focus on superior design, flexible buildouts and best-in-class amenities. 

Breakthrough targets LEED Gold certification at all its U.S. developments and BREEAM Outstanding across its U.K. and European Union projects. In 2025, the Global Real Estate Sustainability Benchmark (GRESB) ranked Breakthrough first amongst its Americas group peers in the Technology/Science sector, highlighting the team’s commitment to delivering high quality, sustainable research campuses for its clients. 

In addition to creating and cultivating full-service ecosystems, Breakthrough provides access to life science industry pioneers and mentorship services from its world-renowned Scientific Advisory Board and an extensive venture capital network.

About Breakthrough Properties ( btprop.com )
Formed in 2019 as a joint venture between global real estate owner, developer, and investor Tishman Speyer and biotechnology investment firm Bellco Capital, Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough Properties’ mission is to acquire, develop and operate the best life science properties in leading urban technology centers around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer’s decades of global real estate development experience with Bellco Capital’s industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Any such forward-looking statements are subject to risks and uncertainties, and actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Furthermore, Breakthrough Properties disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes. Target returns are neither a guarantee nor a prediction of future performance and are based on various assumptions. No guarantee is made that such assumptions will materialize as expected or that investments will achieve such targeted results. The term “client” as used herein describes a life sciences firm that is a tenant of Breakthrough or other tenant of a property.

Non-U.S. Persons
This press release is not intended to be distributed, directly or indirectly, outside of the U.S. and is not directed at investors located in non-U.S. jurisdictions.

Photo – https://mma.prnewswire.com/media/2824717/Breakthrough_Properties__Torrey_Heights_by_Breakthrough.jpg

BOSTON, Nov. 17, 2025 — Bambusa Therapeutics, Inc. (“Bambusa”), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round.

This Series A-2 financing reflects strong participation from Bambusa’s existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma (an investment platform controlled by KKR). Their continued commitment highlights growing confidence in Bambusa’s highly differentiated bispecific platform, rapid execution, and clinical momentum.

Proceeds will accelerate the development of BBT003 and BBT004, extending the company’s proven capability to move programs swiftly from concept to the clinic.

“In just 18 months, our team has advanced two bispecific programs, BBT001 and BBT002, from development candidate to clinical proof-of-concept, an unprecedented pace in I&I biologics, demonstrating what a small, highly coordinated team can achieve in a short period of time,” said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics. “This new financing enables us to apply that same momentum to BBT003 and BBT004. Closing the round at a significantly increased valuation is a clear reflection of the strength of our data, the speed and quality of our execution, and the deep conviction from our investors. 2026 will be a catalyst-rich year for Bambusa with more than 10 clinical readouts across multiple I&I indications.”

BBT001 and BBT002 — both built on Bambusa’s half-life-extended bispecific architecture — have progressed into Phase I studies in dermatology and respiratory indications, realizing the founding ambition to create transformative medicines that reshape the I&I landscape. BBT003 and BBT004 will be developed in gastroenterology and rheumatology, leveraging the same development engine that has driven Bambusa’s early clinical velocity.

Dr. Derek DiRocco, Partner at RA Capital Management, commented: “RA Capital Management is delighted to continue to support Bambusa as they progress their portfolio of potentially best-in-disease bispecific antibodies for various I&I indications deeper into the clinic. In the nine months since we led the Series A-1 financing, we have been thrilled with the rapid and flawless execution delivered by the Bambusa team. Over the next year we eagerly look forward to the extensive clinical data sets that will highlight the immense value across the Bambusa portfolio.”   

Key uses of proceeds:

• Advance BBT003 and BBT004 through IND-enabling studies and into early clinical development, maintaining Bambusa’s pace of advancement.
• Broaden Bambusa’s bispecific antibody platform into new I&I indications and deepen the pipeline.
• Strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics. For more information, visit www.bambusatx.com.

• BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase I development for atopic dermatitis and other Type 2 inflammatory skin diseases.
• BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with best-in-disease potential. It is currently in Phase I development for Type 2 inflammatory disorders including COPD, asthma, CRSwNP, eosinophilic esophagitis, and food allergy.
• BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

SOURCE Bambusa Therapeutics, Inc.

New Funding to Accelerate Platform Growth, Support New Feature Development, and Expand Geographic Reach

MENLO PARK, Calif., Nov. 17, 2025 — Shipday, a global delivery and logistics technology platform serving small and medium-sized businesses (“SMBs”), today announced it has raised $7 million in Series A funding co-led by ECP Growth (“ECP”), a leading growth stage investment firm focused on products, solutions, and technologies across the consumer value chain, and Ibex Investors Mobility VC (“Ibex”), an early-stage venture capital fund focused on mobility, logistics, and manufacturing, with additional participation from B Capital and Supply Chain Ventures. The company previously raised a seed round from B Capital in 2023, bringing its total funding to over $10 million.

Designed for restaurants and other local retailers, Shipday’s platform enables merchants to manage direct delivery orders efficiently while maximizing profitability and improving customer loyalty. With this new funding, Shipday will deepen its investments in new platform features and integrations, agentic AI automations, and an expanded geographic reach, furthering the company’s goal to offer instant access to modern delivery automation solutions to businesses of all sizes across the globe. Among these innovations is AgentFlow, Shipday’s new AI-powered automation engine that functions as a self-driving operating system for local deliveries. By leveraging intelligent agents to streamline dispatch, customer support, and marketing, AgentFlow empowers small businesses to run more efficiently and scale faster.

Since completing its seed funding round in 2023, Shipday has continued to successfully scale its platform globally with more than 5,000 businesses in over 100 countries worldwide, and the platform is available in 30 languages.

“This milestone marks a pivotal moment for Shipday as we continue to scale our platform to meet the growing needs of SMBs navigating complex delivery logistics,” said Moin Islam, Co-Founder and CEO at Shipday. “We’re thrilled to partner with ECP Growth and Ibex, who understand the operational challenges many SMBs face and share our vision for scalable, intuitive logistics technology. Their strategic guidance and deep sector expertise will help us accelerate innovation and reach more customers globally.”

“In an increasingly digital-driven marketplace, Shipday’s mission of empowering SMBs to reach more customers though scalable logistics solutions resonated deeply with ECP’s investment approach,” said Jeff Emmons, Director at ECP Growth. “Shipday’s AI-enabled platform is purpose-built to drive efficiency, mobility, and resource efficiency and to create sustainable value for businesses as they scale. We’re excited to co-lead this investment alongside Ibex, and we look forward to working closely with the Shipday team to expand the platform’s impact.”

“Shipday is equipping SMBs with the necessary tools to compete and win in the last-mile delivery space that has seen explosive growth and high consumer expectations. We’re proud to partner with the company and ECP Growth to co-lead the Series A,” said Jeff Peters, Partner at Ibex Investors and Head of Mobility VC. “We look forward to supporting Shipday as it accelerates its growth and redefines what’s possible for last-mile logistics.”

About Shipday
Shipday is a global delivery and logistics technology platform serving small and medium-sized businesses in over 100 countries. Shipday partners with restaurants, bakeries, grocers, flower shops, and other local merchants to streamline their local delivery logistics and enhance customer satisfaction through AI-powered delivery automation and customer engagements. In addition to serving SMBs, the platform has capabilities to power direct delivery for large, global franchise brands, providing flexibility for businesses of all sizes. For more information, please visit www.shipday.com.

About ECP Growth
ECP Growth is a growth stage investment firm that partners with entrepreneurial businesses creating products, solutions, and technologies across the consumer value chain. ECP Growth takes a thematic approach to investing in companies that sit within resilient categories and have attractive growth fundamentals, with a goal of long-term value creation. For more information, please visit www.ECPgrowth.com

About Ibex Investors
Ibex Investors is a US-based investment firm focused on distinct geographic and thematic strategies and manages a variety of private funds. Ibex is headquartered in Denver, CO, with investment professionals spread across New York, Tel-Aviv, and Silicon Valley.

The Ibex Mobility Revolution VC strategy focuses on high-conviction early-stage investments in mobility, logistics, and manufacturing startups.

More information on Ibex Investors can be found at www.ibexinvestors.com

Contacts:

Shipday
Moin Islam
[email protected]
415-770-3352

ECP Growth
Marissa Foray
[email protected]
203-321-5461

Kate Thompson / Heather Milke
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Ibex Investors
Lian Swirsky
[email protected]
+972-50-2846262

SOURCE Shipday

BluePill builds “AI consumers” — digital twins of real audiences — that accurately predict how people will react to products, campaigns, and ideas in minutes at 90% lower cost.

SEATTLE, Nov. 17, 2025 — BluePill, the AI platform building “AI consumers” to replace traditional market research, today announced it has raised $6 million in seed funding led by Ubiquity Ventures, with participation from Pioneer Square Labs and Flying Fish Ventures.

BluePill solves a fundamental challenge: knowing which new product will succeed, which campaign will perform, and which packaging or activation will drive engagement. It replaces expensive, weeks-long studies by accurately simulating how thousands of “digital-twin” AI consumers react to new products, campaigns, and ideas in minutes. All insights are continuously benchmarked against live human panels, with humans in the loop to ensure accuracy.

“The $140 billion market-research industry is broken,” said Ankit Dhawan, Founder & CEO of BluePill. “At Amazon, I saw what customers did but not why they did it — that gap inspired BluePill. Our AI consumers uncover those motivations instantly, and when combined with human validation, deliver accuracy traditional research can’t match.”

BluePill: AI Consumers That Think Like Real People

BluePill’s AI consumers are built from millions of data points — including behavioral signals, interviews, and surveys — to think and decide like real customers. Brands use them to test concepts, packaging, and creative campaigns in minutes, not weeks. Recent simulations have shown over 90% alignment with live human panels, continuously validated through side-by-side benchmarking.

Early Customers Validate Results

Leading CPG, media, entertainment, healthcare, and sports organizations are already using BluePill to accelerate decision-making.

Kettle & Fire, the #1 bone-broth brand in the U.S., and Magic Spoon, the leading DTC cereal brand, use BluePill to validate new flavors, product concepts, and packaging.

“BluePill insights matched our live panel results, in minutes and at a fraction of the cost,” said Leah Swalling, Director of Brand Management at Kettle & Fire. “We’ve used it to test packaging, explore new flavors, and refine product concepts. We love how quickly we can tap into our customers’ minds and iterate.”

The Seattle Mariners are collaborating with BluePill to simulate fan behavior and predict how new engagement strategies and sponsorships will affect fans.

“We’re excited to partner with BluePill to unlock new ways of creating meaningful experiences for our fans,” said Chris Kennedy, SVP Strategy & Analytics at the Seattle Mariners. “By simulating fan reactions at scale, we can test ideas quickly and cost-effectively, helping us deliver more of what our fans love faster than ever before.”

Scaling Human Insight, Not Replacing It

Human focus groups and surveys suffer from bias, fatigue, fraud, and small sample sizes that don’t represent broader markets. A 20-person focus group reflects 20 opinions — often dominated by the loudest voices in the room. AI consumers, trained on millions of real-world data points and interview responses, provide far more representative consumer insights.

“We’re not replacing human insight; we’re scaling it,” Dhawan said. “Thousands of AI consumers built on real-world data give a far more accurate picture of behavior than any single focus group.”

Investors See Massive Market Potential

“Predicting consumer behavior is the holy grail of marketing,” said Sunil Nagaraj, Founding Partner at Ubiquity Ventures, who led the investment. “The BluePill team has combined deep customer understanding with advanced AI to finally enable brands to know what their customers will love.”

Nagaraj previously led the seed round for Seattle-based Auth0, which exited for $6.5 billion.

BluePill will expand into vertical-specific AI audiences across CPG, healthcare, sports, media, and entertainment, each continuously validated against human benchmarks.

“Imagine your office filled with your actual customers,” Dhawan said. “You’d ask them what they think before every big decision. That’s what BluePill enables — an always-on focus group of your consumers, accessible anytime.”

About BluePill

BluePill is an AI-powered consumer-insights platform that builds AI consumers — digital twins of real audiences — enabling brands to test products, messaging, and creative concepts in minutes. Its insights are continuously validated against human responses, with humans in the loop to ensure accuracy and relevance. Based in Seattle, BluePill is backed by Ubiquity Ventures, Flying Fish Ventures, and Pioneer Square Labs.
Learn more at https://blue-pill.ai.

About Ubiquity Ventures

Ubiquity Ventures is a Silicon Valley–based seed-stage venture firm managing about $200 million in assets. It backs technical founders building AI software that solves business problems beyond the reach of traditional software. Visit https://www.ubiquity.vc.

Media Contact
Sage Quiamno
[email protected]
+1 (808) 232-1321

SOURCE BluePill Inc.

• The second fund closes at nearly four times the size of The LegalTech Fund’s (TLTF) inaugural $28.5 million fund.
• The fund has invested in more than 80 entrepreneurs making the $1 trillion legal services industry faster, smarter, and more accessible.
• McDermott Will & Schulte doubles down as lead investor in TLTF’s second fund, joined by other industry strategics.

FT. LAUDERDALE, Fla., Nov. 17, 2025 — The LegalTech Fund (TLTF), the first and only fund exclusively focused on investing in legal technology companies, today announced the close of its second fund at $110 million. This represents a fourfold expansion over Fund I ($28.5 million). Leading global law firm and Anchor Partner McDermott Will & Schulte reinvests with $10 million, enabling the firm to partner with TLTF’s entrepreneurs on the ideas and technologies that will define the future of legal services. Strategic partner Consilio, a global leader in legal technology solutions and enterprise legal services, also joined as a lead investor, reinforcing its commitment to legal innovation.

The close marks a rare achievement in today’s challenging venture capital environment, reflecting strong investor conviction that the legal industry is entering a sustained era of technology-driven transformation. It highlights the growing recognition of legal technology as a durable investment category and a key driver reshaping how legal services are delivered.

The $1 trillion global legal services market is being fundamentally transformed by technology, workflow automation, and regulatory change. Over the next decade, law firms and in-house legal teams will see their business models tested and redefined, creating new categories of companies and expanding access to legal support. Where only a fractional percent of consumers could once afford legal help, technology is now making services available to millions. Following waves of modernization in fintech, healthtech, and insurtech, legaltech is emerging as the next major vertical undergoing systemic change.

“We launched TLTF to help entrepreneurs transforming the world of law realize their vision, and we are doing just that,” said Zach Posner, Co-Founder and Managing Partner of The LegalTech Fund. “Legal technology is no longer niche; it is starting to be understood that it sits at the center of every business transaction. Our strategic partners’ investments put them in a strong and unique position to lead the industry’s transformation and ultimately create more value for their clients.”

“The world of law is at an inflection point that will transform our industry. We’re committed to driving that disruption, not being disrupted by it,” said Ira Coleman, Chairman of McDermott Will & Schulte. “Our continued partnership with The LegalTech Fund gives us access to the latest innovations shaping the future of law and enables us to deliver maximum impact for our clients globally.”

Fund II attracted a diverse mix of institutional and strategic investors, with participation from partners including Consilio, Burford Capital, Clio, Docusign, Harbor, Orrick, Thomson Reuters Ventures and several others.

“By investing in The LegalTech Fund, we’re putting millions of dollars behind driving innovation across the ecosystem. Our goal is to help build a marketplace where clients have access to the greatest companies and the best technology solutions, creating an environment that accelerates innovation and delivers real choice,” said Andy Macdonald, CEO of Consilio.

TLTF’s second fund continues to invest globally in early-stage startups up to Series A, and has already backed companies redefining every corner of the legal ecosystem. Such companies include Wexler, which provides the AI platform for complex litigation; Entegrata, which helps legal teams utilize AI and analytics; Flo Recruit, which modernizes legal hiring; and HelloPrenup, which expands access to affordable legal planning. Other companies such as BlackCloak, SimpleClosure and Intelligent Legal Solutions are reshaping the delivery, security and scalability of both the business and practice of law through automation and AI.

About The LegalTech Fund
Founded in 2021, The LegalTech Fund is the first venture fund solely dedicated to backing companies transforming the legal industry. TLTF invests globally in early-stage legaltech up to Series A, helping founders reimagine how legal services are practiced, accessed, and delivered. With a global network spanning law firms, corporates, and innovators—and initiatives such as the TLTF Summit and The LegalTech Lab—TLTF is shaping the next decade of legal innovation.

About McDermott Will & Schulte
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.

About Consilio
Consilio is the global leader in eDiscovery, document review, flexible legal talent, and legal advisory & transformation services. Through its Aurora Digital Enterprise Platform, the company empowers multinational corporations and law firms to reduce risk, improve efficiency, and drive better outcomes. Aurora integrates advanced AI — including Guided AI Review, Native AI Review, AI Investigation, and TrueLaw narrative AI — into a unified platform that provides freedom, deep project visibility, and control. Consilio operates offices, review centers, and data centers across Europe, Asia, and North America.

Media Contacts
For The LegalTech Fund
Rebecca Engel
[email protected]
720-840-3061

For McDermott Will & Schulte
Marissa Gallo
[email protected]
212-610-7081

For Consilio
Celia Dewyer
[email protected] 

SOURCE The LegalTech Fund

New AKA Studio consolidates organisational knowledge, incorporates sensory evaluation, and applies AI assistants to guide formulation and optimisation

AMSTELVEEN, Netherlands, Nov. 17, 2025 — AKA Foods Ltd. today announced the completion of a 17.2 million dollar seed funding round led by renowned AI experts and entrepreneurs Alex and Michael Bronstein. The funding marks the official launch of AKA Studio, a secure AI system and proprietary platform that enables food companies to create, optimise, and launch products much faster, smarter, and more affordably than ever before.

Designed to transform how food products are researched, formulated and developed, AKA Studio consolidates a company’s own knowledge and ongoing R&D into a structured foundation. This incorporates experimental and analytical measurements related to texture, aroma and taste from dedicated sensory research facilities, before applying AI assistants to guide formulation and optimisation.

For research and development teams, this integration shortens the innovation cycle from years to weeks by combining historical and ongoing R&D data, ingredient specifications, sensory feedback and regulatory documentation into a unified, intelligent framework. For business leaders, it transforms organisational knowledge into measurable innovation assets that improve productivity and profitability. For investors, it represents a defensible, category-defining technology at the intersection of AI and food science, augmented by sensory evaluation.

Formulation remains a hands-on scientific process. AKA Studio accelerates it and improves decision quality. And, by linking structured digital information with sensory evidence, AKA Studio enables companies to optimise formulations scientifically and bring healthier, more sustainable products to market with greater precision and security. The platform also supports reformulation for clean labels, reduced sugar and fat content, and more resilient supply chains.

Security and confidentiality are central to the system’s design. AKA Studio operates as a secure SaaS platform managed by AKA Foods, giving clients private environments for their data. For organisations with heightened security requirements, it can also be deployed on-premise, air-gapped, under the same protection standards. Client data is never shared or used for model training, and in every case, clients retain full ownership and control of their proprietary information.

Professor Alex Bronstein* , Chief Scientist at AKA Foods, Head of the Center for Intelligent Systems at the Technion – Israel Institute of Technology and a Professor at the Institute of Science and Technology Austria, said:

“AKA Foods is essentially bringing to market a new type of a grammar; a language for food, creating AI agents that are capable of connecting to different external data sources and then making recommendations on how to improve the recipe. This is something that a generic AI model like ChatGPT will never be able to achieve.”

David Sack, Founder & CEO of AKA Foods, added:

“The global food industry holds enormous amounts of valuable knowledge but struggles to use it effectively. AKA Studio gives companies the ability to capture, organise and apply that knowledge securely. This investment allows us to expand deployment to enterprise clients worldwide and continue advancing the science behind how food is created.”

The underlying sensory-AI framework also holds potential for future applications in flavour, fragrance, cosmetics and pharmaceuticals, where sensory evaluation and precision formulation are equally critical.

AKA Studio establishes a new standard for secure, data-driven food innovation, giving research teams, executives and investors a shared pathway to measurable progress in both science and business performance.

To learn more about AKA Foods’ platform and to hear from Professor Alex Bronstein, please see link to video here.

*Professor Alex Bronstein contributes in dual capacities as Chief Scientist and investor, reflecting his increased involvement in the company’s scientific and strategic direction.

About AKA Foods

AKA Foods is a pioneering foodtech company transforming how new food products are created. Its proprietary platform combines advanced artificial intelligence with real human sensory data to accelerate research and development across taste, texture and aroma. Unlike generic AI tools, AKA integrates each company’s tacit knowledge and disparate data sources into a private and secure system. This unique approach enables food companies to shorten development cycles, cut costs and deliver better products that consumers love.

SOURCE AKA Foods Ltd.

ISTANBUL, Nov. 14, 2025 — Karpowership has successfully secured a $400 million syndicated facility for its affiliate Sea World Energy Holdings Limited (“Sea World”), with The Mauritius Commercial Bank Limited (“MCB”) acting as the Sole Mandated Lead Arranger and Account Bank. This transaction marks a major milestone in Karpowership’s financial strategy and underscores the company’s ability to attract innovative, large-scale financing solutions that align with its business model and growth objectives.

The facility represents Karpowership’s first portfolio financing, a bespoke structure designed to reflect the company’s dynamic business model and global operating footprint. The syndicated facility was well received by the market and oversubscribed with strong participation from regional and international lenders. The transaction underscores the confidence of the financial community in Karpowership’s long-term operational track record.

“The successful closing of this $400 million syndicated facility represents a significant milestone in our capital strategy and reflects the confidence that leading regional and international financial institutions place in our operational excellence and delivery record. It reflects our long-standing, trust-based operations in Africa,” said Tuğrul Öz, Karpowership’s Finance Executive Director. “This first portfolio financing enhances our balance sheet efficiency and provides the flexibility to support our continued growth across Africa. We value the longstanding relationship with the lenders that have committed to the transaction and appreciate their participation in this tailored structure, which is aligned with our strategic objectives,” Öz added.

Representing 1% of the world’s total gas-to-power installed capacity, Karpowership has a global footprint across 20 countries in 4 continents, including Africa, where it currently operates in 8 countries.

“This bespoke transaction stands as a testament to the capabilities of MCB in understanding and supporting its clients’ strategy by offering Karpowership Group an integrated and innovative financing solution, while ensuring continued access to investors,” said Mathieu Delteil, Global Head of Structured Finance at MCB.

For more information on Karpowership and its innovative floating power solutions, visit https://www.karpowership.com/.

About Karpowership

Karpowership is a global energy company specializing in fast-track and integrated power solutions. As the world’s largest builder, owner and operator of floating power plants, Karpowership’s vessels can deliver turnkey energy solutions wherever they are needed, connecting to the grid and generating electricity in less than 30 days. In addition to its signature Powerships, Karpowership offers floating LNG solutions, to support a cleaner, more flexible energy future. With over 25 years of experience, Karpowership remains committed to delivering sustainable and reliable power, empowering nations and communities.

Logo: https://mma.prnewswire.com/media/2823475/Karpowership_Logo.jpg

SOURCE Karpowership

Investment will deepen product offerings and deliver next-generation solutions to an underserved museum market

MIAMI, Nov. 14, 2025 — Muse Software, the unified operations management platform powering the future of museums and cultural attractions, today announced it has raised $4.5 million in seed funding to accelerate product innovation and expand its suite of operational tools. The round was led by Roo Capital, with participation from Banter Capital and FJ Labs.

Muse Software provides museums with a single, integrated platform for ticketing, fundraising, CRM, retail / café, and event management. The company’s mission is to replace fragmented, outdated systems with a modern solution that simplifies operations, drives revenue, and strengthens engagement with visitors and donors.

“Muse was founded to bring modern technology and intelligence to museums, a sector that has long been underserved by technology,” said Travis Fuller, Founder and CEO of Muse Software. “This funding enables us to expand our product capabilities and deliver solutions that genuinely impact our customers. We build intuitive, easy-to-use products that automate manual tasks, supported by a hands-on Client Delivery team that ensures our solutions work seamlessly for every museum.”

Muse is focused on tackling manual processes that slow museum operations. The platform automates time-consuming tasks such as generating donor acknowledgement letters, identifying potential donors, managing waitlists, and reconciling financial data with integrated accounting systems – saving museum teams hours of manual work every week. By removing these operational bottlenecks, Muse allows staff to focus on mission-critical activities and meaningful engagement with their audiences.

“We believe technology should do more than streamline operations, it should help bring as much life as possible to the museum. With Muse, we create a data layer than hasn’t existed before, so we are able to build technology to act on those insights,” said Fuller.

“Travis and his team are building what museums have long needed, a unified, modern platform that transforms how cultural institutions operate and engage their communities.” said Nate DaPore, Founder & Managing Partner at Roo Capital. “By creating a powerful data layer that connects every system, Muse is helping museums unlock new insights and revenue opportunities. We look forward to bringing Roo Capital’s resources to help them scale rapidly and lead this category.”

Muse plans to use the new capital to accelerate product development, enhance core functionality, and continue listening closely to its customers to deliver the features museums need. The company is also focused on providing unmatched customer support, helping institutions maximize revenue from admissions, memberships, donations, and events.

About Muse Software
Muse is a modern operations management platform purpose-built for museums, zoos, aquariums, and other nonprofit attractions. Our unified platform includes GA and timed-entry ticketing, CRM, fundraising, merchandise & café point-of-sale, front desk operations, integrated payments, event / camp / workshop management, and more.

Located in Encinitas, CA and Miami, FL — powering cultural institutions worldwide.

https://www.musesoftware.ai/

About Roo Capital

Roo Capital is a Miami-based venture capital firm investing in category-defining companies across cybersecurity, healthcare, and vertical SaaS / AI. The firm’s differentiated model combines Capital, Talent, and Growth through its integrated platform: Roo Search, an executive search arm that helps founders attract top leadership talent, and Roo Growth, an operating group focused on accelerating go-to-market execution and scaling efficiency.

Roo Capital partners with exceptional founders building enduring software platforms that deliver real-world impact. Its portfolio includes breakout companies leading their categories such as Steer, GoTu, and Scamnetic.

For more information, visit www.roocapital.com.

SOURCE Muse Software